Pfizer to acquire King Pharmaceuticals for $3.6 billion
This article was originally published in Scrip
Executive Summary
Pfizer is to acquire the pain-focused specialty pharma firm King Pharmaceuticals for $3.6 billion in cash, or $14.25 per share, which represents a premium of around 40% to King's closing share price on 11 October, and 46% to the one-month average closing price.